The value of radioembolisation therapy on metastatic liver tumours – a single centre experience
Nuklearmedizin - NuclearMedicine · 01.06.2023 · 62 (03) · 214-219
DOI: 10.1055/a-2026-0851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2023. Verfasst von Ozgul Ekmekcioglu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
Local treatments used in metastatic liver tumours efficiently control the disease and survival. Transarterial radioembolisation (TARE) is a safely used locoregional treatment method. We aim to investigate the impact of TARE on different kinds of metastatic liver tumours and the effect of pre-treatment clinical findings. Material and Methods The patients with metastatic liver tumours referred to our department for radioembolisation were retrospectively evaluated. All patients were given a Y-90 glass microsphere after being selected by the appropriate clinical and imaging criteria, lung shunt fraction levels, vascular investigation, and macro aggregated albumin (MAA) scintigraphy performed in the angiography unit.
Results
Thirty-four (17 women, 17 men) patients were suitable for the treatment. Patients were treated with 115.88±47.84 Gy Y-90 glass Microspheres. The mean survival rate was 14.59±12.59 months after treatment. Higher survival rates were detected in patients who had higher pre-treatment serum albumin levels. The optimum cut-off value of albumin to predict response to treatment was 4 g/dl with 88.89% sensitivity, 62.50% specificity, 72.73% PPV and 83.33% NPV. Furthermore, one unit increase in age increased mortality 1.152 times in our patient group.
Conclusion
Radioembolisation is a safe and efficient method for controlling metastatic liver disease. Albumin levels significantly affect predicting response; higher albumin levels are related to higher survival rates. Furthermore, older age positively correlated with mortality rates in our patient group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye.
- Interventional Radiology Department, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye.
- Radiation Oncology, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye.
- Hepatobiliary and General Surgery, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye.
Zitieren
APA
Ekmekcioglu, O., Erdem, U., Arican, P., Ozvar, H., & Bostanci, O. (2023). The value of radioembolisation therapy on metastatic liver tumours – a single centre experience. Nuklearmedizin - NuclearMedicine, 62(03), 214-219. https://doi.org/10.1055/a-2026-0851
Vancouver
Ekmekcioglu O, Erdem U, Arican P, Ozvar H, Bostanci O. The value of radioembolisation therapy on metastatic liver tumours – a single centre experience. Nuklearmedizin - NuclearMedicine. 2023;62(03):214-219. doi:10.1055/a-2026-0851
BibTeX
@article{Ekmekcioglu2023,
author = {Ekmekcioglu, Ozgul and Erdem, Umut and Arican, Pelin and Ozvar, Hikmet and Bostanci, Ozgur},
title = {The value of radioembolisation therapy on metastatic liver tumours – a single centre experience},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2023},
volume = {62},
number = {03},
pages = {214--219},
doi = {10.1055/a-2026-0851}
}
EUVIMED